Chemours Reiterated 2026 Guidance but Investors Wanted Stronger Signal, RBC Says

MT Newswires Live05-12

Chemours (CC) reiterating its 2026 guidance may be viewed as weaker than peers, and investors may have been looking for a stronger signal from management of an H2 boost, RBC Capital Markets said in a note emailed Monday.

Chemours secured a long-term chlorine supply contract with Olin (OLN) starting in 2028, aimed at strengthening its competitive position, the firm said. By that time, the PCC plant is expected to come online and deliver solid cost benefits for the company, according to the note.

While the company should benefit from the Middle East conflict-driven sulfur cost inflation impacting sulfate-based TiO2 competitors, price has yet to boost earnings, which should start in H2, the brokerage added.

RBC kept an outperform rating on Chemours and raised the price target to $29 from $26.

Price: 25.31, Change: +2.27, Percent Change: +9.85

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment